Zolgensma
Payments companies reported to CMS as associated with Zolgensma. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zolgensma, per program year, as reported to CMS.
Who makes it
- Novartis Gene Therapies, INC. (Fka Avexis, INC.) $212K associated with Zolgensma (2023-2025)
- Novartis Pharmaceuticals Corporation $145K associated with Zolgensma (2023-2025)
- Novartis Pharma Ag $50K associated with Zolgensma (2023-2025)
- Novartis Gene Therapies, INC. (Fka Avexis, INC.) $2,691 associated with Zolgensma (2023-2025)
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zolgensma
These are the largest totals companies reported as associated with Zolgensma. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Richard Finkel | Memphis, TN | Neurology With Special Qualifications In Child Neurology | $69,125.67 |
| John Day | Stanford, CA | Neuromuscular Medicine (Psychiatry & Neurology) | $25,798.89 |
| Perry Shieh | Los Angeles, CA | Neurology (Psychiatry & Neurology) | $22,486.30 |
| Crystal Proud | Norfolk, VA | Neurology With Special Qualifications In Child Neurology | $19,936.00 |
| Darryl Devivo | New York, NY | Neurology With Special Qualifications In Child Neurology | $17,471.37 |
| Julie Parsons | Aurora, CO | Neurology With Special Qualifications In Child Neurology | $15,892.18 |
| Sean Tunis | Baltimore, MD | $15,332.29 | |
| Lauren Elman | Philadelphia, PA | Neurology (Psychiatry & Neurology) | $14,881.75 |
| Ana Tesi Rocha | Palo Alto, CA | Neuromuscular Medicine (Psychiatry & Neurology) | $14,571.39 |
| Leslie Nelson | Desoto, TX | Internal Medicine | $13,994.34 |
Prescribed Zolgensma?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.